GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland.
Adult
Aged
Aged, 80 and over
Biopsy, Fine-Needle
DNA-Binding Proteins
/ genetics
Exome
False Positive Reactions
Female
Gene Rearrangement
Genome-Wide Association Study
Genomics
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Male
Middle Aged
Mutation
PAX8 Transcription Factor
/ genetics
Repressor Proteins
/ genetics
Retrospective Studies
Sequence Analysis, RNA
Thyroid Cancer, Papillary
/ genetics
Thyroid Gland
/ pathology
Thyroid Neoplasms
/ genetics
Trans-Activators
/ genetics
GLIS1
GLIS3
hyalinizing trabecular tumor
thyroid
Journal
Thyroid : official journal of the American Thyroid Association
ISSN: 1557-9077
Titre abrégé: Thyroid
Pays: United States
ID NLM: 9104317
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
17
1
2019
medline:
13
2
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Hyalinizing trabecular tumor (HTT) is a rare thyroid neoplasm with a characteristic trabecular growth pattern and hyalinization. This lesion has been the subject of long-term controversy surrounding its genetic mechanisms, relationship to papillary thyroid carcinoma (PTC), and malignant potential. Due to the presence of nuclear features shared with PTC, HTT frequently contributes to a false-positive cytology, which hampers patient management. The goal of this study was to apply genome-wide sequencing analyses to elucidate the genetic mechanisms of HTT and its relationship to PTC. Whole-exome, RNA-Seq, and targeted next-generation sequencing analyses were performed to discover and characterize driver mutations in HTT. RNA-Seq results were used for pathway analysis. Tissue expression of GLIS3 and other proteins was detected by immunohistochemistry. The prevalence of GLIS fusions was studied in 17 tumors initially diagnosed as HTT, 220 PTC, and 10,165 thyroid fine-needle aspiration samples. Using whole-exome and RNA-Seq analyses of the initial three HTT, no known thyroid tumor mutations were identified, while in-frame gene fusion between PAX8 exon 2 and GLIS3 exon 3 was detected in all tumors. Further analysis identified PAX8-GLIS3 in 13/14 (93%) and PAX8-GLIS1 in 1/14 (7%) of HTT confirmed after blind pathology review. The fusions were validated by Sanger sequencing and FISH. The fusions resulted in overexpression of the 3'-portion of GLIS3 and GLIS1 mRNA containing intact DNA-binding domains of these transcription factors and upregulation of extracellular matrix genes including collagen IV. Immunohistochemistry confirmed upregulation and deposition of collagen IV and pan-collagen in HTT. The analysis of 220 PTC revealed no PAX8-GLIS3 and one PAX8-GLIS1 fusion. PAX8-GLIS3 was prospectively identified in 8/10,165 (0.1%) indeterminate cytology fine-needle aspiration samples; 5/5 resected fusion-positive nodules were HTT on surgical pathology. This study demonstrates that GLIS rearrangements, particularly PAX8-GLIS3, are highly prevalent in HTT but not in PTC. The fusions lead to overexpression of GLIS, upregulation of extracellular matrix genes, and deposition of collagens, which is a characteristic histopathologic feature of HTT. Due to unique genetic mechanisms and an indolent behavior, it is proposed to rename this tumor as "GLIS-rearranged hyalinizing trabecular adenoma."
Sections du résumé
BACKGROUND
Hyalinizing trabecular tumor (HTT) is a rare thyroid neoplasm with a characteristic trabecular growth pattern and hyalinization. This lesion has been the subject of long-term controversy surrounding its genetic mechanisms, relationship to papillary thyroid carcinoma (PTC), and malignant potential. Due to the presence of nuclear features shared with PTC, HTT frequently contributes to a false-positive cytology, which hampers patient management. The goal of this study was to apply genome-wide sequencing analyses to elucidate the genetic mechanisms of HTT and its relationship to PTC.
METHODS
Whole-exome, RNA-Seq, and targeted next-generation sequencing analyses were performed to discover and characterize driver mutations in HTT. RNA-Seq results were used for pathway analysis. Tissue expression of GLIS3 and other proteins was detected by immunohistochemistry. The prevalence of GLIS fusions was studied in 17 tumors initially diagnosed as HTT, 220 PTC, and 10,165 thyroid fine-needle aspiration samples.
RESULTS
Using whole-exome and RNA-Seq analyses of the initial three HTT, no known thyroid tumor mutations were identified, while in-frame gene fusion between PAX8 exon 2 and GLIS3 exon 3 was detected in all tumors. Further analysis identified PAX8-GLIS3 in 13/14 (93%) and PAX8-GLIS1 in 1/14 (7%) of HTT confirmed after blind pathology review. The fusions were validated by Sanger sequencing and FISH. The fusions resulted in overexpression of the 3'-portion of GLIS3 and GLIS1 mRNA containing intact DNA-binding domains of these transcription factors and upregulation of extracellular matrix genes including collagen IV. Immunohistochemistry confirmed upregulation and deposition of collagen IV and pan-collagen in HTT. The analysis of 220 PTC revealed no PAX8-GLIS3 and one PAX8-GLIS1 fusion. PAX8-GLIS3 was prospectively identified in 8/10,165 (0.1%) indeterminate cytology fine-needle aspiration samples; 5/5 resected fusion-positive nodules were HTT on surgical pathology.
CONCLUSIONS
This study demonstrates that GLIS rearrangements, particularly PAX8-GLIS3, are highly prevalent in HTT but not in PTC. The fusions lead to overexpression of GLIS, upregulation of extracellular matrix genes, and deposition of collagens, which is a characteristic histopathologic feature of HTT. Due to unique genetic mechanisms and an indolent behavior, it is proposed to rename this tumor as "GLIS-rearranged hyalinizing trabecular adenoma."
Identifiants
pubmed: 30648929
doi: 10.1089/thy.2018.0791
pmc: PMC6389773
doi:
Substances chimiques
DNA-Binding Proteins
0
GLIS3 protein, human
0
PAX8 Transcription Factor
0
PAX8 protein, human
0
Repressor Proteins
0
Trans-Activators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-173Subventions
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097190
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181150
Pays : United States
Références
Lab Invest. 2005 Sep;85(9):1065-75
pubmed: 15980887
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Protoc. 2016 Dec;11(12):2529-2548
pubmed: 27854363
PLoS Genet. 2016 Aug 05;12(8):e1006239
pubmed: 27494611
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cytojournal. 2006 Jul 25;3:17
pubmed: 16867191
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Rev Cancer. 2004 Mar;4(3):177-83
pubmed: 14993899
Diagn Mol Pathol. 1996 Mar;5(1):45-52
pubmed: 8919545
Mod Pathol. 1999 Nov;12(11):1057-61
pubmed: 10574603
Histopathology. 2010 Apr;56(5):632-40
pubmed: 20459574
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D428-32
pubmed: 15608231
Nat Genet. 2006 Jun;38(6):682-7
pubmed: 16715098
Bioinformatics. 2011 Oct 15;27(20):2903-4
pubmed: 21840877
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Cell Mol Life Sci. 2018 Oct;75(19):3473-3494
pubmed: 29779043
Ultrasonography. 2016 Apr;35(2):131-9
pubmed: 26639939
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Histopathology. 2008 Mar;52(4):529-31
pubmed: 18315612
Am J Surg Pathol. 2000 Dec;24(12):1615-21
pubmed: 11117781
Thyroid. 2011 Mar;21(3):253-9
pubmed: 21190434
Stat Med. 2004 Jun 30;23(12):1921-86
pubmed: 15195324
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7
pubmed: 14681473
Best Pract Res Clin Endocrinol Metab. 2017 Mar;31(2):175-182
pubmed: 28648506
J Clin Invest. 2017 Dec 1;127(12):4326-4337
pubmed: 29083325
Adv Anat Pathol. 2002 Jan;9(1):7-11
pubmed: 11756755
Am J Surg Pathol. 2008 Dec;32(12):1877-89
pubmed: 18813121
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Eur J Cancer. 2005 Mar;41(5):816-21
pubmed: 15763659
J Clin Pathol. 2017 Aug;70(8):641-647
pubmed: 28424236
Cancer. 2018 Apr 15;124(8):1682-1690
pubmed: 29345728
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Bioinformatics. 2012 Jul 1;28(13):1805-6
pubmed: 22543366
Hum Pathol. 1997 Dec;28(12):1366-72
pubmed: 9416692
Hum Pathol. 1994 Feb;25(2):192-7
pubmed: 8119720
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Nucleic Acids Res. 2013 Jan;41(Database issue):D920-4
pubmed: 23161685
Nat Rev Endocrinol. 2015 Jan;11(1):29-42
pubmed: 25350068
Genome Res. 2008 Nov;18(11):1851-8
pubmed: 18714091
Ultrastruct Pathol. 1998 Jan-Feb;22(1):39-46
pubmed: 9491214
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Am J Surg Pathol. 1987 Aug;11(8):583-91
pubmed: 2441614
Am J Surg Pathol. 2000 Dec;24(12):1622-6
pubmed: 11117782
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Oncotarget. 2017 Aug 18;8(44):77041-77049
pubmed: 29100368
Am J Surg Pathol. 2004 Jul;28(7):859-67
pubmed: 15223954
Cytopathology. 2011 Dec;22(6):407-13
pubmed: 21733000
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Gastroenterology. 2018 Jun;154(8):2060-2063.e8
pubmed: 29486199
Endocr Pathol. 1991 Jun;2(2):83-91
pubmed: 32138392
Bioinformatics. 2015 Jan 15;31(2):268-70
pubmed: 25273102